MEDNAX, Inc., together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians. The company also provides maternal-fetal care services, including inpatient and office-based clinical care to expectant mothers and unborn babies through affiliated maternal-fetal medicine subspecialists, as well as obstetricians and other clinicians, including maternal-fetal nurse practitioners, certified nurse mid-wives, ultrasonographers, and genetic counselors. In addition, it offers pediatric cardiology care services comprising inpatient and office-based pediatric cardiology care of the fetus, infant, child, and adolescent patient with congenital heart defects and acquired heart disease, as well as adults with congenital heart defects through affiliated pediatric cardiologist subspecialists and other related clinical professionals; and specialized cardiac care to the fetus, neonatal and pediatric patients. Further, the company provides other pediatric subspecialty care services through pediatric subspecialists, such as pediatric intensivists, pediatric hospitalists, pediatric surgeons, and pediatric ophthalmologists, as well as pediatric ear, nose, and throat physicians; and support services in the areas of hospitals, primarily in the pediatric emergency rooms, labor and delivery areas, and nursery and pediatric departments. As of March 16, 2021, it operated a network of approximately 2,300 physicians. The company was founded in 1979 and is based in Sunrise, Florida.
IPO Year:
Exchange: NYSE
Website: mednax.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/16/2024 | Outperform | Macquarie | |
| 9/26/2024 | $8.00 → $14.00 | Hold → Buy | Jefferies |
| 6/7/2024 | $8.00 | Sell → Hold | Deutsche Bank |
| 2/23/2022 | $32.00 → $31.00 | Outperform | Credit Suisse |
| 12/22/2021 | $33.00 → $32.00 | Outperform | Credit Suisse |
| 11/4/2021 | $29.00 → $27.00 | Market Perform | SVB Leerink |
| 9/27/2021 | $29.00 | Market Perform | SVB Leerink |
| 8/9/2021 | $30.00 → $32.00 | Neutral | Mizuho |
| 6/23/2021 | $30.00 | Hold | Stifel |
Raises Full Year 2025 Adjusted EBITDA Outlook Range Pediatrix Medical Group, Inc. (NYSE:MD), a leading provider of physician services, today reported earnings of $0.24 per share for the three months ended March 31, 2025. On a non-GAAP basis, Pediatrix reported Adjusted EPS of $0.33. For the 2025 first quarter, Pediatrix reported the following results: Net revenue of $458 million; Net income of $21 million; and Adjusted EBITDA of $49 million. "Our strong first quarter results reflect same-unit top-line outperformance versus our expectations, continued steady cost management and the successful results of the portfolio restructuring we completed last year. As a result of our strong f
Pediatrix Medical Group, Inc. (NYSE:MD) will host an investor conference call and webcast on Tuesday, May 6, 2025 at 9:00 a.m. ET to discuss results from operations for the quarter ended March 31, 2025. A detailed press release will be issued the morning of May 6, 2025 before the securities markets open. The investor conference call will be webcast and can be accessed at Pediatrix's website, www.pediatrix.com/investors. ABOUT PEDIATRIX MEDICAL GROUP Pediatrix® Medical Group, Inc. (NYSE:MD) is a leading provider of physician services. Pediatrix-affiliated clinicians are committed to providing coordinated, compassionate and clinically excellent services to women, babies and children across
Pediatrix Medical Group, Inc. (NYSE:MD), a leading provider of physician services, today reported earnings of $0.36 per share for the three months ended December 31, 2024. On a non-GAAP basis, Pediatrix reported Adjusted EPS of $0.51. For the 2024 fourth quarter, Pediatrix reported the following results: Net revenue of $502 million; Net income of $30 million; and Adjusted EBITDA of $69 million. "Our strong fourth quarter results reflect continued top-line outperformance versus our expectations, the completion of our portfolio restructuring, and the related overhead expense reductions," said Mark S. Ordan, Chief Executive Officer of Pediatrix Medical Group. "I am honored and excited
As the preterm birth rate remains at an all-time high, continuing education for providers of neonatal intensive care is critical Pediatrix® Medical Group, Inc. (NYSE:MD), a leading provider of physician services, is pleased to announce NEO: The Conference for Neonatology, a premier educational event dedicated to advancing the field of neonatology. The conference will be held Feb. 19-21 in Las Vegas, Nevada, and will bring together neonatologists, pediatricians, advanced practitioners and allied health professionals from around the globe. As a trusted provider of neonatology services for more than 45 years, Pediatrix cares for nearly a quarter of the infants born in the United States tha
Pediatrix Medical Group, Inc. (NYSE:MD) will host an investor conference call and webcast on Thursday, February 20, 2025 at 9:00 a.m. ET to discuss results from operations for the quarter ended December 31, 2024. A detailed press release will be issued the morning of February 20, 2025 before the securities markets open. The investor conference call will be webcast and can be accessed at Pediatrix's website, www.pediatrix.com/investors. ABOUT PEDIATRIX MEDICAL GROUP Pediatrix® Medical Group, Inc. (NYSE:MD) is a leading provider of physician services. Pediatrix-affiliated clinicians are committed to providing coordinated, compassionate and clinically excellent services to women, babies
Executive Chair Mark S. Ordan to Return as Chief Executive Officer Company Redoubles Strategic Focus on Physician Practices and Hospital and Health System Relationships Pediatrix Medical Group, Inc. (NYSE:MD) ("Pediatrix" or "the Company"), a leading provider of physician services, today announced a leadership transition to accelerate its progress in executing a transformational strategy designed to create value for shareholders and other stakeholders. To best position Pediatrix to implement the strategy, which is based on recommitting to the highest standards in clinical excellence and strengthening the Company's hospital relationships, the Company's Board of Directors has appointed Ex
Pediatrix Medical Group, Inc. (NYSE:MD), a leading provider of physician services, today reported earnings of $0.23 per share for the three months ended September 30, 2024. On a non-GAAP basis, Pediatrix reported Adjusted EPS of $0.44. For the 2024 third quarter, Pediatrix reported the following results: Net revenue of $511 million; Net income of $19 million; and Adjusted EBITDA of $60 million. "Our third quarter operating results modestly exceeded our expectations, driven primarily by strength in same-unit revenue," said James D. Swift, M.D., Chief Executive Officer of Pediatrix Medical Group. "During the quarter, we successfully completed our previously announced transition to a
Pediatrix Medical Group, Inc. (NYSE:MD) will host an investor conference call and webcast on Friday, November 1, 2024 at 9:00 a.m. ET to discuss results from operations for the quarter ended September 30, 2024. A detailed press release will be issued the morning of November 1, 2024 before the securities markets open. The investor conference call will be webcast and can be accessed at Pediatrix's website, www.pediatrix.com/investors. ABOUT PEDIATRIX MEDICAL GROUP Pediatrix® Medical Group, Inc. (NYSE:MD) is a leading provider of physician services. Pediatrix-affiliated clinicians are committed to providing coordinated, compassionate and clinically excellent services to women, babies and ch
Pediatrix Medical Group, Inc. (NYSE:MD), a leading provider of physician services, today reported a loss of $1.84 per share for the three months ended June 30, 2024. On a non-GAAP basis, Pediatrix reported Adjusted EPS of $0.34. For the 2024 second quarter, Pediatrix reported the following results: Net revenue of $504 million; Net loss of $153 million; and Adjusted EBITDA of $58 million. "Our second quarter operating results exceeded our expectations and reflected stable patient volumes, improved payor mix, and operating efficiencies," said James D. Swift, M.D., Chief Executive Officer of Pediatrix Medical Group. "Our previously discussed portfolio management plans are well un
Pediatrix Medical Group, Inc. (NYSE:MD) will host an investor conference call and webcast on Tuesday, August 6, 2024 at 9:00 a.m. ET to discuss results from operations for the quarter ended June 30, 2024. A detailed press release will be issued the morning of August 6, 2024 before the securities markets open. The investor conference call will be webcast and can be accessed at Pediatrix's website, www.pediatrix.com/investors. ABOUT PEDIATRIX MEDICAL GROUP Pediatrix® Medical Group, Inc. (NYSE:MD) is a leading provider of physician services. Pediatrix-affiliated clinicians are committed to providing coordinated, compassionate and clinically excellent services to women, babies and childre
Macquarie initiated coverage of Pediatrix Medical Group with a rating of Outperform
Jefferies upgraded Pediatrix Medical Group from Hold to Buy and set a new price target of $14.00 from $8.00 previously
Deutsche Bank upgraded Pediatrix Medical Group from Sell to Hold and set a new price target of $8.00
Credit Suisse reiterated coverage of Mednax with a rating of Outperform and set a new price target of $31.00 from $32.00 previously
Credit Suisse reiterated coverage of Mednax with a rating of Outperform and set a new price target of $32.00 from $33.00 previously
SVB Leerink reiterated coverage of Mednax with a rating of Market Perform and set a new price target of $27.00 from $29.00 previously
SVB Leerink initiated coverage of Mednax with a rating of Market Perform and set a new price target of $29.00
Mizuho reiterated coverage of Mednax with a rating of Neutral and set a new price target of $32.00 from $30.00 previously
Stifel resumed coverage of MEDNAX with a rating of Hold and set a new price target of $30.00
Citigroup reiterated coverage of Mednax with a rating of Neutral and set a new price target of $34.00 from $22.00 previously
8-K - Pediatrix Medical Group, Inc. (0000893949) (Filer)
10-Q - Pediatrix Medical Group, Inc. (0000893949) (Filer)
8-K - Pediatrix Medical Group, Inc. (0000893949) (Filer)
8-K - Pediatrix Medical Group, Inc. (0000893949) (Filer)
DEFA14A - Pediatrix Medical Group, Inc. (0000893949) (Filer)
DEF 14A - Pediatrix Medical Group, Inc. (0000893949) (Filer)
10-K - Pediatrix Medical Group, Inc. (0000893949) (Filer)
8-K - Pediatrix Medical Group, Inc. (0000893949) (Filer)
8-K - Pediatrix Medical Group, Inc. (0000893949) (Filer)
8-K - Pediatrix Medical Group, Inc. (0000893949) (Filer)
Raises Full Year 2025 Adjusted EBITDA Outlook Range Pediatrix Medical Group, Inc. (NYSE:MD), a leading provider of physician services, today reported earnings of $0.24 per share for the three months ended March 31, 2025. On a non-GAAP basis, Pediatrix reported Adjusted EPS of $0.33. For the 2025 first quarter, Pediatrix reported the following results: Net revenue of $458 million; Net income of $21 million; and Adjusted EBITDA of $49 million. "Our strong first quarter results reflect same-unit top-line outperformance versus our expectations, continued steady cost management and the successful results of the portfolio restructuring we completed last year. As a result of our strong f
Pediatrix Medical Group, Inc. (NYSE:MD) will host an investor conference call and webcast on Tuesday, May 6, 2025 at 9:00 a.m. ET to discuss results from operations for the quarter ended March 31, 2025. A detailed press release will be issued the morning of May 6, 2025 before the securities markets open. The investor conference call will be webcast and can be accessed at Pediatrix's website, www.pediatrix.com/investors. ABOUT PEDIATRIX MEDICAL GROUP Pediatrix® Medical Group, Inc. (NYSE:MD) is a leading provider of physician services. Pediatrix-affiliated clinicians are committed to providing coordinated, compassionate and clinically excellent services to women, babies and children across
Pediatrix Medical Group, Inc. (NYSE:MD), a leading provider of physician services, today reported earnings of $0.36 per share for the three months ended December 31, 2024. On a non-GAAP basis, Pediatrix reported Adjusted EPS of $0.51. For the 2024 fourth quarter, Pediatrix reported the following results: Net revenue of $502 million; Net income of $30 million; and Adjusted EBITDA of $69 million. "Our strong fourth quarter results reflect continued top-line outperformance versus our expectations, the completion of our portfolio restructuring, and the related overhead expense reductions," said Mark S. Ordan, Chief Executive Officer of Pediatrix Medical Group. "I am honored and excited
Pediatrix Medical Group, Inc. (NYSE:MD) will host an investor conference call and webcast on Thursday, February 20, 2025 at 9:00 a.m. ET to discuss results from operations for the quarter ended December 31, 2024. A detailed press release will be issued the morning of February 20, 2025 before the securities markets open. The investor conference call will be webcast and can be accessed at Pediatrix's website, www.pediatrix.com/investors. ABOUT PEDIATRIX MEDICAL GROUP Pediatrix® Medical Group, Inc. (NYSE:MD) is a leading provider of physician services. Pediatrix-affiliated clinicians are committed to providing coordinated, compassionate and clinically excellent services to women, babies
Pediatrix Medical Group, Inc. (NYSE:MD), a leading provider of physician services, today reported earnings of $0.23 per share for the three months ended September 30, 2024. On a non-GAAP basis, Pediatrix reported Adjusted EPS of $0.44. For the 2024 third quarter, Pediatrix reported the following results: Net revenue of $511 million; Net income of $19 million; and Adjusted EBITDA of $60 million. "Our third quarter operating results modestly exceeded our expectations, driven primarily by strength in same-unit revenue," said James D. Swift, M.D., Chief Executive Officer of Pediatrix Medical Group. "During the quarter, we successfully completed our previously announced transition to a
Pediatrix Medical Group, Inc. (NYSE:MD) will host an investor conference call and webcast on Friday, November 1, 2024 at 9:00 a.m. ET to discuss results from operations for the quarter ended September 30, 2024. A detailed press release will be issued the morning of November 1, 2024 before the securities markets open. The investor conference call will be webcast and can be accessed at Pediatrix's website, www.pediatrix.com/investors. ABOUT PEDIATRIX MEDICAL GROUP Pediatrix® Medical Group, Inc. (NYSE:MD) is a leading provider of physician services. Pediatrix-affiliated clinicians are committed to providing coordinated, compassionate and clinically excellent services to women, babies and ch
Pediatrix Medical Group, Inc. (NYSE:MD), a leading provider of physician services, today reported a loss of $1.84 per share for the three months ended June 30, 2024. On a non-GAAP basis, Pediatrix reported Adjusted EPS of $0.34. For the 2024 second quarter, Pediatrix reported the following results: Net revenue of $504 million; Net loss of $153 million; and Adjusted EBITDA of $58 million. "Our second quarter operating results exceeded our expectations and reflected stable patient volumes, improved payor mix, and operating efficiencies," said James D. Swift, M.D., Chief Executive Officer of Pediatrix Medical Group. "Our previously discussed portfolio management plans are well un
Pediatrix Medical Group, Inc. (NYSE:MD) will host an investor conference call and webcast on Tuesday, August 6, 2024 at 9:00 a.m. ET to discuss results from operations for the quarter ended June 30, 2024. A detailed press release will be issued the morning of August 6, 2024 before the securities markets open. The investor conference call will be webcast and can be accessed at Pediatrix's website, www.pediatrix.com/investors. ABOUT PEDIATRIX MEDICAL GROUP Pediatrix® Medical Group, Inc. (NYSE:MD) is a leading provider of physician services. Pediatrix-affiliated clinicians are committed to providing coordinated, compassionate and clinically excellent services to women, babies and childre
Pediatrix Medical Group, Inc. (NYSE:MD), the nation's leading provider of highly specialized health care for women, children and babies, today reported earnings of $0.05 per share for the three months ended March 31, 2024. On a non-GAAP basis, Pediatrix reported Adjusted EPS of $0.20. For the 2024 first quarter, Pediatrix reported the following results: Net revenue of $495 million; Net income of $4 million; and Adjusted EBITDA of $37 million. "Our first quarter operating results were in line with our expectations," said James D. Swift, M.D., Chief Executive Officer of Pediatrix Medical Group. "Our key priorities for 2024 are sharply focused on operating efficiency and stabiliz
Pediatrix Medical Group, Inc. (NYSE:MD) will host an investor conference call and webcast on Tuesday, May 7, 2024 at 9:00 a.m. ET to discuss results from operations for the quarter ended March 31, 2024. A detailed press release will be issued the morning of May 7, 2024 before the securities markets open. The investor conference call will be webcast and can be accessed at Pediatrix's website, www.pediatrix.com/investors. ABOUT PEDIATRIX MEDICAL GROUP Pediatrix® Medical Group, Inc. (NYSE:MD) is the nation's leading provider of physician services. Pediatrix-affiliated clinicians are committed to providing coordinated, compassionate and clinically excellent services to women, babies and c
Executive Chair Mark S. Ordan to Return as Chief Executive Officer Company Redoubles Strategic Focus on Physician Practices and Hospital and Health System Relationships Pediatrix Medical Group, Inc. (NYSE:MD) ("Pediatrix" or "the Company"), a leading provider of physician services, today announced a leadership transition to accelerate its progress in executing a transformational strategy designed to create value for shareholders and other stakeholders. To best position Pediatrix to implement the strategy, which is based on recommitting to the highest standards in clinical excellence and strengthening the Company's hospital relationships, the Company's Board of Directors has appointed Ex
Pediatrix Medical Group, Inc. (NYSE:MD), the nation's leading provider of highly specialized health care for women, children and babies, today announced that its board of directors has appointed Sylvia Young, a recognized leader in healthcare and long-term healthcare executive, as an independent director, effective May 12, 2023. Ms. Young, a veteran of hospital administration since 1985, most recently served as President and CEO of the HCA Continental Division, a multi-state regional healthcare system that is part of Hospital Corporation of America (HCA). Prior to her appointment to the Denver-based Division headquarters, Ms. Young served as President of HCA's Sunrise Health System, inclu
PALM BEACH, Fla., July 15, 2021 (GLOBE NEWSWIRE) -- BurgerFi International, Inc. (NASDAQ:BFI, BFIIW))) ("BurgerFi" or the "Company"), one of the nation's fastest-growing premium fast-casual concepts, has appointed Vivian Lopez-Blanco to its board of directors, effective July 14, 2021. Lopez-Blanco's appointment follows the sudden passing of board member Steven Berrard announced on June 10, 2021. Lopez-Blanco has also been named as the chair of the audit committee and will be serving on the compensation committee and nominating governance committee. Lopez-Blanco is an experienced board member and seasoned finance executive with expertise in organizational transformations and driving prof
SC 13G - Pediatrix Medical Group, Inc. (0000893949) (Subject)
SC 13G/A - Pediatrix Medical Group, Inc. (0000893949) (Subject)
SC 13G/A - Pediatrix Medical Group, Inc. (0000893949) (Subject)
SC 13G/A - Pediatrix Medical Group, Inc. (0000893949) (Subject)
SC 13G/A - Pediatrix Medical Group, Inc. (0000893949) (Subject)
SC 13G - Pediatrix Medical Group, Inc. (0000893949) (Subject)
SC 13G/A - Pediatrix Medical Group, Inc. (0000893949) (Subject)
SC 13G/A - Pediatrix Medical Group, Inc. (0000893949) (Subject)
SC 13G/A - Pediatrix Medical Group, Inc. (0000893949) (Subject)
SC 13D/A - Pediatrix Medical Group, Inc. (0000893949) (Subject)
4 - Pediatrix Medical Group, Inc. (0000893949) (Issuer)
4 - Pediatrix Medical Group, Inc. (0000893949) (Issuer)
4 - Pediatrix Medical Group, Inc. (0000893949) (Issuer)
4 - Pediatrix Medical Group, Inc. (0000893949) (Issuer)
4 - Pediatrix Medical Group, Inc. (0000893949) (Issuer)
4 - Pediatrix Medical Group, Inc. (0000893949) (Issuer)
4 - Pediatrix Medical Group, Inc. (0000893949) (Issuer)
4 - Pediatrix Medical Group, Inc. (0000893949) (Issuer)
3 - Pediatrix Medical Group, Inc. (0000893949) (Issuer)
4 - Pediatrix Medical Group, Inc. (0000893949) (Issuer)